Journal of Medicinal Chemistry

Structure-Based Design of Highly Selective β -Secretase Inhibitors: Synthesis, Biological Evaluation, and Protein–Ligand X-ray Crystal Structure

Arun K. Ghosh,^{*,†} Kalapala Venkateswara Rao,[†] Navnath D. Yadav,[†] David D. Anderson,[†] Navnath Gavande,[†] Xiangping Huang,[‡] Simon Terzyan,[‡] and Jordan Tang[‡]

[†]Department of Chemistry and Department of Medicinal Chemistry, Purdue University, 560 Oval Drive, West Lafayette, Indiana 47907, United States

[‡]Protein Studies Program, Oklahoma Medical Research Foundation, University of Oklahoma Health Science Center, 825 NE 13th Street, MS 28, Oklahoma City, Oklahoma 73104, United States

(5) Supporting Information

ABSTRACT: The structure-based design, synthesis, and X-ray structure of protein-ligand complexes of exceptionally potent and selective β -secretase inhibitors are described. The inhibitors are designed specifically to interact with S_1' active site residues to provide selectivity over memapsin 1 and cathepsin D. Inhibitor 5 has exhibited exceedingly potent inhibitory activity ($K_i = 17 \text{ pM}$) and high selectivity over BACE 2 (>7000-fold) and cathepsin D (>250000-fold). A protein-ligand crystal structure revealed important molecular insight into these



selectivities. These interactions may serve as an important guide to design selectivity over the physiologically important aspartic acid proteases.

INTRODUCTION

Alzheimer's disease (AD) is a progressive, degenerative brain disorder with no effective treatment to date, and the development of new drugs is an urgent priority in medicine.¹ The hallmark of AD is the formation of neutritic plaques containing 40/42 residue amyloid- β (A β) peptides and neurofibrillary tangles in the brain.² β -Secretase [memapsin 2, β -site APP cleaving enzyme 1 (BACE 1)] is one of two proteases that cleaves β -amyloid precursor protein (APP) and generates $A\beta$ and its aggregation product.³ There is considerable evidence that excess $A\beta$ leads to brain inflammation, neuronal death, and AD.⁴ Consequently, β secretase has become a major therapeutic target for drug development.^{5,6} Since our design of initial transition-state inhibitor (1, Figure 1) and subsequent determination of inhibitor-bound memapsin 2 X-ray structure, nearly a decade ago, steady progress has been made toward the evolution of potent small molecule and brain-penetrable inhibitor drugs.^{7,8} Recently, we have shown that administration of β -secretase inhibitor 2 rescued cognitive decline in transgenic AD mice, validating β -secretase as an important drug design target.^{9,10} However, the development of clinical β -secretase inhibitor drug is faced with numerous formidable challenges, including lack of selectivity against other physiologically important aspartic acid proteases and issues of poor pharmacological profiles including blood-brain penetration.^{7,8} In our continuing work toward the design of potent small molecule and selective inhibitors, we have been particularly interested in developing tools for selectivity against relevant physiologically important aspartic acid proteases, especially cathepsin D (CD) and β -site APP



Figure 1. Structures of β -secretase inhibitors 1–3.

Special Issue: Alzheimer's Disease

Received: June 22, 2012

cleaving enzyme 2 (BACE 2). BACE 2 has specificity similarity to BACE 1, and this is known to have important physiological functions.¹¹ CD plays a key role in important biological functions like protein catabolism.¹² The abundance of CD in various cells, especially in central nervous system tissue cells, is very high. Furthermore, CD gene knockout studies in mice showed marked phenotypic response including high mortality rate.¹³ Therefore, the selective inhibition of β -secretase over CD and BACE 2 is very critical to reduce toxicity and other side effects of β -secretase inhibitor drugs.

As described by us previously, the X-ray crystal structure of inhibitor 1-bound β -secretase showed an interesting hydrogen bonding between the P₂'-carbonyl and the hydroxyl of Tyr-198, forming a rare kink at the P2' site.8 We have exploited this interaction in the design and synthesis of very potent and highly selective β -secretase inhibitors such as 3 by incorporating hydroxyethylene isosteres.¹⁴ However, the cellular β -secretase inhibitory activity of this class of inhibitors was only in the micromolar range. In an attempt to design small molecule inhibitors with improved selectivity and cellular activity exploiting this unique interaction, we have further explored β secretase inhibitors with a reduced amide isostere and incorporated functionality to improve potency and selectivity. The basic amine functionality in the reduced amide isostere may also improve cell permeability.¹⁵ Herein, we report our structure-based design and synthesis of very potent and exceptionally selective inhibitors with excellent cellular inhibitory properties. A protein-ligand X-ray structure provided important molecular insight into the specific cooperative ligand-binding site interactions for selectivity.

The inhibitors containing reduced amide isostere have been reported; however, they exhibited only marginal selectivity against memapsin 1 (BACE 2).^{6,16} A reduced amide β -secretase inhibitor 4 was synthesized by us, and this compound has exhibited a BACE 1 K_i of 27 nM and marginal selectivity against BACE 2 and CD in our in-house enzyme inhibitory assays. An energy-minimized model of 4 was created based upon the protein–ligand X-ray structure of 2-bound β -secretase.⁹ Our preliminary model suggested that an introduction of a hydroxyl group with S-configuration on the ethyl group of homoalanine moiety would make enhanced interactions in the active site and possibly enhance selectivity. On the basis of this molecular insight, we have designed, synthesized, and evaluated inhibitors 5 and 6 (Figure 2) to investigate the influence of the hydroxyl group and also the role



Figure 2. Structure of isophthalamide-derived β -secretase inhibitors 4–9.

of stereochemistry on the potency and selectivity. We have also synthesized and evaluated inhibitors 7-9 to examine the importance of various functional groups at the P_1 ' and P_2 ' sites on the potency.

CHEMISTRY

The synthesis of inhibitors 4-6 is shown in Scheme 1. Amino acids 10a-c were coupled with isobutyl amine in the presence





of EDC, HOBt, and ⁱPr₂NEt to afford the corresponding amides in 71–91% yield. Removal of the Boc group with trifluoroacetic acid followed by reductive amination of the resulting amine with aldehyde 11^{17} provided compounds 12a– c in 49–76% yields. Treatment of 12a–c with trifluoroacetic acid followed by coupling with acid 13^{18} provided the inhibitors 4-6 in 68–75% yields.

The synthesis of inhibitors 7–9 is shown in Schemes 2 and 3. Coupling of Boc-protected allothreonine derivative **10b** with *N*-

Scheme 2. Synthesis of Inhibitors 7 and 8



isobutyl-*N*-methyl amine using EDC, HOBt, and ⁱPr₂NEt followed by Boc removal using trifluoroacetic acid afforded (2S,3S)-2-amino-3-hydroxy-*N*-isobutyl-*N*-methyl-butanamide in 49% yield over two steps. Reductive amination of this amine with known aldehyde **11** provided **12d** in 30% yield. Inhibitor 7 was synthesized in 61% yield from **12d** by Boc removal using trifluoroacetic acid followed by coupling of the resulting amine with the known acid **13** (Scheme 2). As shown in Scheme 2, inhibitor **8** was prepared from **15** following the similar reaction sequence utilized for the synthesis of inhibitors **4**–7 (Schemes 1 and 2). Compound **15**, in turn, has been synthesized by O-

Scheme 3. Synthesis of Inhibitor 9



methylation of 14 using MeI and Ag₂O¹⁹ followed by hydrolysis using aqueous LiOH.

The synthesis of inhibitor 9 has been carried out as shown in Scheme 3. Treatment of 14 with TBSOTf in the presence of Et_3N followed by reaction with DiBALH provided the corresponding aldehyde. Reductive amination of this crude aldehyde with isobutyl amine afforded 16 in 66% yield over three steps. Removal of the Boc group using trifluoroacetic acid followed by reductive amination of the resulting amine with the aldehyde 11 afforded compound 17.

Reaction of compound 17 with trifluoroacetic acid followed by coupling with acid 13 using EDC, HOBt, and Pr_2NEt provided TBS-protected inhibitor, which upon treatment with TBAF gave the inhibitor 9 in 46% yield over three steps. On the basis of the results obtained from these inhibitors, we have directed our attention to reduce the peptidic nature of 5 by keeping all of the key hydrogen-bonding interactions of the prime region intact. In this direction, we have designed and synthesized the inhibitors 18–22 (Figure 3) containing 7,6,5tricyclic indole moieties as P₂ ligands.



Figure 3. Structure of indole-derived β -secretase inhibitors 18–22.

For the synthesis of inhibitor **18**, known indolecarboxylic acid **23** was prepared as described in the literature.²⁰ The synthesis of α, α -dimethyl tricyclic indole derivative **25**, present in inhibitor **20**, was synthesized as shown in Scheme 4. Reaction of the known tricyclic indole derivative **24**²¹ with MeI in the presence of NaH provided the corresponding α, α -dimethyl derivative. Saponification of the resulting ester with aqueous NaOH afforded α, α -dimethylindole carboxylic acid **25** (37% yield over two steps). Inhibitor **18** was synthesized by treatment of Boc derivative **12b** with trifluoroacetic acid followed by coupling of the resulting amine with acid **23**²⁰ (68% yield). Similarly, coupling of the above amine with cyclopropyl indole derivative **30** provided inhibitor **21**.

Scheme 4. Synthesis of Carboxylic Acid 25 and Inhibitors 18 and 21



The synthesis of tricyclic indole derivative in inhibitors 21 and 22 has been carried out from butyl 3-chloropropanesulfonate 26 as shown in Scheme 5. In a one-pot two-step





reaction, **26** was treated first with BuLi followed by treatment again with BuLi, and BOMCl provided the corresponding butyl 1-(benzyloxymethyl)cyclopropanesulfonate in 80% yield. Hydrolysis of this sulfonate with KSCN followed by refluxing of the resulting potassium sulfonate with SOCl₂ afforded sulfonyl chloride **27** in 91% yield over two steps. Reaction of indole derivative **28**²² with **27** in the presence of pyridine and a catalytic amount of DMAP furnished sulfonamide **29** in 74% yield. Hydrogenolysis of **29**, followed by mesylation of the resulting alcohol using mesyl chloride and Et₃N, afforded the corresponding mesylate. This mesylate was subjected to a one-pot cyclization and N-methylation using NaH and MeI followed by hydrolysis in the presence of aqueous NaOH to obtain the desired carboxylic acid **30** in 65% yield over two steps.

The synthesis of (2S,3S)-2-amino-3-hydroxy-*N*-isobutyl (or isopropyl)hexanamide moiety present in the prime region of the inhibitors **19**, **20**, and **22** has been carried out as shown in Scheme 6. Asymmetric dihydroxylation of **31** using AD-mix α followed by reaction of the resulting dihydroxy compound with *p*-nitrobenzenesulfonyl chloride in the presence of Et₃N afforded nosylate **32** in 32% yield over two steps.²³ Treatment

Scheme 6. Synthesis of Inhibitors 19, 20, and 22



of 32 with NaN₃ followed by hydrogenation of the corresponding azide using 10% Pd–C in the presence of $(Boc)_2O$ afforded 33 in 80% yield. Hydrolysis using aqueous LiOH followed by coupling with isobutyl amine and isopropyl amine using EDC, HOBt, and 'Pr₂NEt afforded 34a and 34b, respectively. Boc removal using trifluoroacetic acid followed by reductive amination of the resulting amine with aldehyde 11 gave 35a and 35b in 49 and 74% yields, respectively. Inhibitors 19, 20, and 22 were synthesized by coupling of the amine, obtained by Boc removal of 35a and 35b using trifluoroacetic acid, with tricyclic indole derivatives 23 or 25 or 30.

RESULTS AND DISCUSSION

The BACE 1 inhibitory activity of synthetic inhibitors 4-9 was determined against recombinant β -secretase using our previously reported assay protocols.²⁴ The results are shown in Table 1. As can be seen, inhibitor 4 with a homoalanine P_1 side chain has shown a K_i of 27 nM (entry 1). Inhibitor 5 with an allothreonine P1' side chain has exhibited remarkable BACE 1 inhibitory activity with a K_i of 17 pM (entry 2). Inhibitor 6 with a threonine P₁' side chain has shown significant reduction of BACE 1 activity over the deoxyderivative 4 or the inhibitor 5 with an allothreonine P_1' side chain (entries 1-3). We have also evaluated the cellular inhibition of β -secretase in neuroblastoma cells.²⁵ Consistent with potent BACE 1 inhibitory activity, inhibitor 5 exhibited an average cellular IC_{50} value of 1 nM. The corresponding inhibitor 6 with a threonine P_1' side chain has shown a cellular IC₅₀ value of >1 μ M in the same assay. Inhibitor 7 with a N-methyl amide abolished all BACE 1 inhibitory activity. Inhibitor 8 with an "OMe" group in the P_1' region also showed substantial reduction in inhibitory potency (entry 5) as compared to inhibitor 5 with hydroxyl group. Inhibitor 9 with a reduced amide in the P_2' region resulted in a total loss in potency. These results clearly demonstrate the significance of hydrogenbonding interactions of inhibitor 5 with the prime region of the BACE 1 active site.

To gain further molecular insight, we have determined the Xray structure of 5-bond to β -secretase at a 2.2 Å resolution. As shown in Figure 4, the amine functionality of the reduced amide isostere forms two tight hydrogen bonds (2.4 and 2.7 Å bond distances) with active site aspartic acid Asp228.⁷ Interestingly, the other active site Asp32 is not directly interacting with the reduced amide isostere. Asp32 is extensively hydrogen bonded to three groups: the amide nitrogen of Gly34 (2.8 Å), the hydroxyl group of Ser35 (2.5-3 Å with rotations of the involved groups), and the amide nitrogen of Gly230 (3.3 Å). These interactions appear to lock Asp32 in a rigid conformation; thus, its hydrogen bonding to Asp228 produced a network of hydrogen bond interactions to include the interaction of the inhibitor and the protease. A similar inhibitor-enzyme interacting pattern has been reported for the crystal structure of reduced amide isosteres.^{16b} The fact that inhibitors 2 and 5 are highly potent suggests that the interaction of both active site carboxyls with the transition-state isostere is not a necessary feature for the design of potent inhibitors. The P3-phenyl ring occupies a unique position that spans S₃ and S₄ subsites and causes a significant positional shift of a protein loop containing residues from 8 to 13 (the 10s $loop)^{26}$ located in the S₃/S₄ pocket similar to inhibitor 2. This flexible part of the active site cleft can be further exploited for ligand design. The P2'-carbonyl as well as P2'-NH are within proximity to form hydrogen bonds with Thr72 and Gly34, respectively. Most significantly, the allothreonine hydroxyl group is oriented toward the Tyr-198 hydroxyl group. This interaction is presumably absent in inhibitor 4. Also, the P₁'hydroxyl group stereochemistry is optimal for critical hydrogen bonding with Tyr-198. The combinations of active site interactions are responsible for the potency and selectivity of inhibitor 5.

The X-ray crystal structure of 5-bound memapsin 2 demonstrates the importance of the allothreonine moiety as it forms key hydrogen-bonding interactions with the prime region of memapsin 2. Therefore, inhibitors 18-22, with a 7,6,5-tricyclicindole moiety as the P₂ ligand, were designed with a view to reduce labile amide bonds in isophthalic acid amidederived ligand. Synthetic inhibitors 18-22 were evaluated against recombinant BACE 1, and the results are summarized in Table 2. Inhibitor 18, containing a known 7,6,5-tricyclic moiety as the P₂ ligand, showed a low nanomolar activity toward BACE 1 (K_i = 7.3 nM). This inhibitor is substantially less potent than inhibitor 5; however, the ratio of cell inhibitory to enzyme inhibitory efficacy was improved significantly (3 vs >58), indicating better cell permeability for compound 18. Inhibitor 19 with a sterically more demanding propyl group in the P_1 ' region has shown around 18-fold improvement in the potency (entries 1 and 2). Inhibitor 20 with a dimethyl-substituted indole derivative as the P_2 ligand resulted in >10-fold potency enhancement over unsubstituted inhibitor 19. This inhibitor exhibited a cellular IC_{50} value of 15 nM. The ligand was also designed especially to halt the possibility of retro-Michael reaction of the P_2 - α , α -unsubstituted sultam functionality in inhibitors 18 and 19.27 Inhibitors 21 and 22, designed by replacing the two methyl groups of P2 ligand in 20 with cyclopropyl group, also exhibited impressive potency.

We then evaluated the potencies of selected inhibitors against recombinant BACE 2 and human CD, and the results are shown in Table 3. Interestingly, inhibitor 5 displayed very impressive selectivity against BACE 2 ($K_i = 120$ nM, selectivity >7000-fold) and CD ($K_i = 4.3 \mu$ M, selectivity >250000-fold) as

Table 1. BACE 1 Inhibitory and Cellular Activity of Inhibitors 4-9



^aThe IC₅₀ was determined in neuroblastoma cells. GRL-8234 exhibited $K_i = 1.8$ nM and IC₅₀ = 2.5 nM in this assay.

well. In comparison, deoxyinhibitor 4 has shown a BACE 2 K_i of 1450 nM (selectivity >55-fold) and CD K_i of 8264 nM (selectivity >300-fold). This result suggested that the allothreonine hydroxyl group on the P_1' side chain is critical to the selectivity and potency of inhibitor 5. Inhibitor 18 has also exhibited good selectivity (over 970-fold selective) toward BACE 1 over CD (entry 3). Inhibitor 19 with a propyl side chain has shown improvement in CD selectivity (entry 4). Inhibitor 20 displayed good selectivity against BACE 2 and

excellent selectivity against CD (entry 5). Inhibitor **22** has also shown a >4200-fold selectivity over CD (entry 6).

In conclusion, we have designed, synthesized, and examined the biological activity of isophthalamide-based BACE 1 inhibitors containing various functional groups in the prime region. The selectivity of inhibitors 4 and 5 against BACE 2 and CD was also examined. Inhibitor 5 with an allothreonine moiety



Figure 4. X-ray structure of **5** (green)-bound- β -secretase complex. Hydrogen bonds are shown in dotted lines (PDB ID: 4GID).

Table 2. BACE 1 Inhibitory and Cellular Activity of Inhibitors 18–22



^{*a*}The IC₅₀ was determined in neuroblastoma cells. GRL-8234 exhibited $K_i = 1.8$ nM and IC₅₀ = 2.5 nM in this assay.

Table 3.	Selectivity 3	Studies	of BACE	1	Inhibitors	against
BACE 2	and CD					

		$K_{\rm i}$ (nM)			selectivity		
entry	inhibitor	BACE 1	BACE 2	CD	BACE 2/ BACE 1	CD/ BACE 1	
1	4	27.12	1450	8264	>55	>300	
2	5	0.017	120	4300	>7000	>250000	
3	18	7.3		7100		>970	
4	19	0.4		690		>1700	
5	20	0.036	11	530	>300	>14700	
6	22	0.47		2000		>4200	

exhibited superior potency and exceptionally high selectivity when compared to inhibitors with a threonine moiety or an ethylglycine (homoalanine) moiety. Inhibitors with N-isobutyl-N-methylamide and P_2' reduced amide groups on the prime side lost their efficacy. These results clearly demonstrate the significance of prime region of the inhibitors on the potency and selectivity. The X-ray structure of 5-bond β -secretase also showed the presence of an effective hydrogen bond between the prime side of the inhibitor and Thr72, Gly34, and Tyr 198 residues of BACE 1. On the basis of this molecular insight, we have further designed and synthesized inhibitors by replacing the isophthalamide moiety with conformationally constrained 7,6,5-tricyclicindole moieties and by keeping the allothreonine moiety intact. These inhibitors have also shown very good potency and selectivity against CD. These results further support the significance of hydrogen-bonding interactions in the prime region for the potency and selectivity. The combination of active site interactions along with the Tyr-198 may be responsible for the observed selectivity. This molecular insight may aid further design of selectivity against other aspartic acid proteases. Further investigations into the origin of selectivity are in progress.

EXPERIMENTAL SECTION

General. All anhydrous solvents were obtained according to the following procedures: diethyl ether and tetrahydrofuran (THF) were distilled from sodium/benzophenone under argon; dichloromethane was from calcium hydride. Other solvents were used without purification. All moisture-sensitive reactions were carried out in flame-dried flasks under an argon atmosphere. Reactions were monitored by thin-layer chromatography (TLC) using Silicycle 60A-F254 silica gel precoated plates. Flash column chromatography was performed using Silicycle 230-400 mesh silica gel. Yields refer to chromatographically and spectroscopically pure compounds. ¹H NMR and ¹³C NMR spectra were recorded on a Varian Inova-300 (300 and 75 MHz, respectively), Bruker Avance ARX-400 (400 and 100 MHz), and Bruker Avance DRX-500 (500 and 125 MHz). High- and lowresolution mass spectra were carried out by the Mass Spectroscopy Center at Purdue University. The purity of all test compounds was determined by HRMS and HPLC analysis. All test compounds showed \geq 95% purity.

Synthesis of Compound 12a. To a mixture of (S)-2-[(tertbutoxycarbonyl)amino]butanoic acid 10a (2.3 mmol, 0.47 g) and ¹Pr₂NEt (2.76 mmol, 0.48 mL) in CH₂Cl₂ (12 mL), HOBt·H₂O (2.76 mmol, 0.37 g), isobutyl amine (2.76 mmol, 0.27 mL), and EDC.HCl (2.76 mmol, 0.53 g) were added simultaneously at 23 °C, and the resulting mixture was stirred for 17 h at 23 °C. The reaction mixture was quenched with saturated aqueous NaHCO₃ solution and extracted with CH₂Cl₂. The combined extracts were dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (1–3% MeOH/CH₂Cl₂) to furnish (*S*)-tert-butyl [1-(*isobutylamino*)-1-oxobutan-2-yl]carbamate in 86% yield (0.51 g). ¹H NMR (400 MHz, $CDCl_3$): δ 6.24 (brs, 1H), 5.08 (brs, 1H), 4.07–3.89 (m, 1H), 3.18–2.96 (m, 2H), 1.92–1.70 (m, 2H), 1.62 (hept, J = 7.3 Hz, 1H), 1.43 (s, 9H), 0.93 (t, J = 7.4 Hz, 3H), 0.89 (d, J = 6.8 Hz, 6H).

To a solution of (S)-tert-butyl [1-(isobutylamino)-1-oxobutan-2-yl]carbamate (1.97 mmol, 0.51 g) in CH₂Cl₂ (9 mL), trifluoroacetic acid (3 mL) was added at 0 °C, and the resulting mixture was stirred for 1.5 h at 23 °C. Excess trifluoroacetic acid and CH₂Cl₂ were removed under reduced pressure, and the resulting residue was purified by silica gel column chromatography [2–5% (5%NH₃/MeOH)/CH₂Cl₂] to furnish (S)-2-amino-*N-iso*butylbutanamide in 96% yield (0.298 g).

To a solution of the above (S)-2-amino-N-isobutylbutanamide (1.87 mmol, 0.296 g) and (S)-tert-butyl (1-oxo-3-phenylpropan-2-yl)carbamate 11 [prepared from the corresponding Weinreb amide (2 mmol) following a similar literature procedure]⁷ in CH₂Cl₂ (20 mL), Na(OAc)₃BH (2.62 mmol, 0.55 g) was added at 0 °C. The resulting mixture was stirred for 1 h at 0 °C and 15 h at 23 °C. The reaction mixture was quenched with saturated aqueous NaHCO3 solution and extracted with CH2Cl2. The combined extracts were dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (1-3%)MeOH/CH₂Cl₂) to furnish the corresponding adduct 12a in 79% yield (0.58 g). ¹H NMR (400 MHz, CDCl₃): δ 7.34-7.26 (m, 2H), 7.25-7.11 (m, 4H), 4.50 (brs, 1H), 3.95 (brs, 1H), 3.10-2.96 (m, 2H), 2.92 (dd, J = 7.3, 5.0 Hz, 1H), 2.86-2.69 (m, 2H), 2.62 (dd, J = 11.9, 4.3 Hz, 1H), 2.52 (dd, J = 12.0, 7.9 Hz, 1H), 1.80–1.63 (m, 2H), 1.63–1.50 (m, 1H), 1.41 (s, 9H), 0.92 (t, J = 7.5 Hz, 3H), 0.85 (d, J = 6.5 Hz. 6H).

Synthesis of Inhibitor 4. To a solution of 12a (0.72 mmol, 0.282 g) in CH₂Cl₂ (9 mL), trifluoroacetic acid (3 mL) was added at 0 °C. After the reaction mixture was stirred for 1 h at 23 °C, CH₂Cl₂ and trifluoroacetic acid were removed under reduced pressure. The resulting residue was purified by silica gel column chromatography $[2-6\% (5\% NH_3/MeOH)/CH_2Cl_2]$ to furnish the corresponding amine in 93% yield (0.195 g).

To a solution of the above amine (0.125 mmol, 36.4 mg) in CH_2Cl_2 (10 mL), ⁱPr₂NEt (0.03 mL), HOBt·H₂O (0.16 mmol, 21.6 mg), (R)-3-(N-methylmethylsulfonamido)-5-[(1-phenylethyl)-carbamoyl]benzoic acid 13 (0.16 mmol, 60.2 mg), and EDC·HCl (0.16 mmol, 30.7 mg) were added simultaneously at 23 °C, and the resulting mixture was stirred for 14 h at the same temperature. The reaction mixture was quenched with saturated aqueous NaHCO3 solution and extracted with CH2Cl2. The combined extracts were dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (1-3% MeOH/CH₂Cl₂) to furnish the inhibitor 4 in 73% yield (59.6 mg). ¹H NMR (400 MHz, CDCl₃): δ 8.26 (s, 1H), 8.03 (s, 1H), 7.98 (s, 1H), 7.48 (d, J = 7.8 Hz, 1H), 7.39–7.34 (m, 2H), 7.33–7.24 (m, 5H), 7.24-7.18 (m, 3H), 6.71 (t, J = 6.2 Hz, 1H), 5.31 (p, J = 7.5Hz, 1H), 4.40-4.26 (m, 1H), 3.29 (s, 3H), 3.04-2.91 (m, 3H), 2.88-2.83 (m, 1H), 2.81 (s, 3H), 2.81–2.73 (m, 2H), 2.55 (dd, J = 12.3, 4.1 Hz, 1H), 1.75–1.58 (m, 2H), 1.57 (d, J = 7.0 Hz, 3H), 1.55–1.48 (m, 1H), 0.89 (t, J = 7.4 Hz, 3H), 0.77 (d, J = 6.7 Hz, 3H), 0.76 (d, J = 6.6 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃): δ 174.15, 165.23, 164.53, 143.06, 142.23, 137.64, 135.65, 129.1, 128.62, 128.58, 127.93, 127.87, 127.33, 126.64, 126.23, 123.39, 65.20, 51.68, 50.24, 49.56, 46.41, 38.55, 37.84, 35.52, 28.36, 26.96, 21.60, 19.98, 19.95, 10.33. HRMS-ESI (m/z): $[M + H]^+$ calcd for $C_{35}H_{48}N_5O_5S$, 650.3376; found, 650.3370.

Synthesis of Compound 12b. tert-Butyl [(2S,3S)-3-hydroxy-1-(isobutylamino)-1-oxobutan-2-yl]carbamate was synthesized in 71% yield by coupling of (2S,3S)-2-[(*tert*-butoxycarbonyl)amino]-3-hydroxybutanoic acid 10b with isobutyl amine in the presence of EDC, HOBt, and ⁱPr₂NEt as described for (S)-tert-butyl [1-(*isobutylamino*)-1-oxobutan-2-yl]carbamate. ¹H NMR (400 MHz, CDCl₃): δ 6.47 (brs, 1H), 5.53 (brs, 1H), 4.10–3.75 (m, 3H), 3.23–3.09 (m, 1H), 3.06– 2.92 (m, 1H), 1.78 (hept, J = 6.7 Hz, 1H), 1.45 (s, 9H), 1.29 (d, J = 6.1 Hz, 3H), 0.91 (d, J = 6.5 Hz, 6H).

Compound **12b** was synthesized in 52% yield (for two steps) from *tert*-butyl [(2S,3S)-3-hydroxy-1-(*iso*butylamino)-1-oxobutan-2-yl]-

carbamate following the procedure described for the synthesis of compound **12a**. ¹H NMR (400 MHz, CDCl₃): δ 7.35–7.27 (m, 3H), 7.26–7.19 (m, 1H), 7.17 (d, *J* = 7.4 Hz, 2H), 4.53 (d, *J* = 8.9 Hz, 1H), 4.05–3.86 (m, 2H), 3.39 (brs, 1H), 3.13–3.00 (m, 2H), 2.99 (d, *J* = 5.7 Hz, 1H), 2.87–2.71 (m, 2H), 2.67 (dd, *J* = 12.1, 4.4 Hz, 1H), 2.58 (dd, *J* = 12.1, 7.6 Hz, 1H), 1.73 (hept, *J* = 6.7 Hz, 1H), 1.41 (s, 9H), 1.18 (d, *J* = 6.5 Hz, 3H), 0.87 (d, *J* = 7.1 Hz, 6H).

Synthesis of Inhibitor 5. Inhibitor 5 has been prepared (yield 71%, over two steps) from 12b by Boc deprotection followed by coupling with (R)-3-(N-methylmethylsulfonamido)-5-[(1-phenylethyl)carbamoyl]benzoic acid 13 following a similar reaction procedure described for the inhibitor 4. ¹H NMR (400 MHz, CDCl₃): δ 8.13 (s, 1H), 7.93 (s, 1H), 7.88 (s, 1H), 7.39-7.27 (m, 6H), 7.26-7.14 (m, 6H), 5.27 (p, J = 7.3 Hz, 1H), 4.48-4.30 (m, 1H), 4.04-3.94 (m, 1H), 3.24 (s, 3H), 3.09 (d, J = 4.3 Hz, 1H), 3.02–2.88 (m, 3H), 2.88– 2.77 (m, 1H), 2.80 (s, 3H), 2.73 (dd, J = 12.4, 3.7 Hz, 1H) 2.64 (dd, J = 12.3, 7.7 Hz, 1H), 1.64 (hept, J = 6.7 Hz 1H), 1.56 (d, J = 6.9 Hz, 3H), 1.04 (d, J = 6.2 Hz, 3H), 0.80 (d, J = 6.8 Hz, 3H), 0.80 (d, J = 6.8 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃): δ 172.37, 166.01, 164.75, 142.91, 142.03, 137.54, 135.90, 135.77, 129.16, 128.65, 128.59, 127.89, 127.62, 127.43, 126.65, 126.23, 123.87, 68.21, 68.06, 52.16, 51.60, 49.66, 46.40, 39.00, 37.83, 35.56, 28.34, 21.65, 20.06, 18.21. HRMS-ESI (m/z): $[M + H]^+$ calcd for $C_{35}H_{48}N_5O_6S$, 666.3325; found, 666.3321.

Synthesis of Compound 12c. tert-Butyl [(2S,3R)-3-hydroxy-1-(isobutylamino)-1-oxobutan-2-yl]carbamate has been synthesized (yield 91%) by coupling of (2S,3R)-2-[(tert-butoxycarbonyl)amino]-3-hydroxybutanoic acid 10c with isobutyl amine in the presence of ⁱPr₂NEt, HOBt, and EDC as described for (*S*)-tert-butyl [1-(isobutylamino)-1-oxobutan-2-yl]carbamate. ¹H NMR (400 MHz, CDCl₃): δ 6.71 (brs, 1H), 5.52 (d, *J* = 7.6 Hz, 1H), 4.45–4.30 (m, 1H), 3.97 (dd, *J* = 8.2, 1.9 Hz, 1H), 3.22–3.08 (m, 1H), 3.07–2.92 (m, 1H), 1.77 (hept, *J* = 6.7 Hz, 1H), 1.45 (s, 9H), 1.18 (d, *J* = 6.4 Hz, 3H), 0.90 (d, *J* = 6.9 Hz, 6H).

Compound **12c** was prepared from *tert*-butyl [(2*S*,3*R*)-3-hydroxy-1-(*iso*butylamino)-1-oxobutan-2-yl]carbamate following the procedure described for the synthesis of compound **12a** (yield 49% over two steps). ¹H NMR (400 MHz, CDCl₃): δ 7.37–7.26 (m, 2H), 7.25–7.13 (m, 4H), 4.59 (d, *J* = 8.5 Hz, 1H), 4.04–3.75 (m, 2H), 3.15–2.96 (m, 2H), 2.94 (d, *J* = 5.2 Hz, 1H), 2.80 (d, *J* = 6.2 Hz, 2H), 2.70–2.55 (m, 2H), 1.92 (brs, 1H), 1.74 (hept, *J* = 6.7 Hz, 1H), 1.40 (s, 9H), 1.18 (d, *J* = 6.3 Hz, 3H), 0.87 (d, *J* = 6.4 Hz, 6H).

Synthesis of Inhibitor 6. Inhibitor 6 has been prepared (yield 75%, over two steps) from 12c by Boc deprotection followed by coupling with (R)-3-(N-methylmethylsulfonamido)-5-[(1-phenylethyl)carbamoyl]benzoic acid 13 following a similar reaction procedure described for the inhibitor 4. ¹H NMR (400 MHz, CDCl₃): δ 8.15 (s, 1H), 7.92 (s, 1H), 7.87 (s, 1H), 7.48 (d, J = 7.7 Hz, 1H), 7.38-7.27 (m, 5H), 7.26–7.15 (m, 5H), 7.08 (t, J = 5.9 Hz, 1H), 5.27 (p, J = 7.1 Hz, 1H), 4.42–4.27 (m, 1H), 3.79 (p, J = 6.3 Hz, 1H), 3.22 (s, 3H), 3.01-2.87 (m, 4H), 2.84 (dd, J = 13.7, 7.7 Hz, 1H), 2.78 (s, 3H), 2.71–2.59 (m, 2H), 1.69–1.59 (m, 1H), 1.56 (d, J = 7.0 Hz, 3H), 1.14 (d, J = 6.2 Hz, 3H), 0.79 (d, J = 6.4 Hz, 3H), 0.78 (d, J = 6.6 Hz, 3H).¹³C NMR (100 MHz, CDCl₃): δ 172.78, 165.82, 164.81, 143.03, 142.05, 137.58, 135.88, 135.77, 129.14, 128.61, 127.78, 127.64, 127.39, 126.64, 126.23, 123.80, 69.13, 68.38, 52.04, 50.90, 49.68, 46.54, 38.59, 37.79, 35.56, 28.33, 21.68, 20.03, 19.68. HRMS-ESI (m/z): $[M + H]^+$ calcd for C35H48N5O6S, 666.3325; found, 666.3335.

Synthesis of Compound 12d. To a mixture of $(2S_3S)$ -2-[(tertbutoxycarbonyl)amino]-3-hydroxybutanoic acid (10b) (1 mmol, 0.22 g) and Pr_2NEt (1.2 mmol, 0.21 mL) in CH₂Cl₂ (5 mL) were added HOBt.H₂O (1.2 mmol, 0.162 g), N-isobutyl-N-methylamine (1.2 mmol, 0.14 mL), and EDC·HCl (1.2 mmol, 0.23 g) at 23 °C, and the resulting reaction mixture was stirred for 15 h at 23 °C. The reaction mixture was quenched with saturated aqueous NaHCO₃ solution and extracted with CH₂Cl₂. The combined extracts were dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (1–3% MeOH/CH₂Cl₂) to obtain *tert*-butyl {(2*S*,3*S*)-3-hydroxy-1-[*iso*butyl-(methyl)amino]-1-oxobutan-2-yl}carbamate. To a solution of the above *tert*-butyl {(2S,3S)-3-hydroxy-1-[*iso*butyl(methyl)amino]-1-oxobutan-2-yl}carbamate in CH₂Cl₂ (6 mL) was added trifluoroacetic acid (2 mL) at 0 °C. The resulting reaction mixture was warmed to 23 °C and stirred for 1.5 h at 23 °C. The reaction mixture was concentrated under reduced pressure, and the resulting residue was purified by silica gel column chromatography [2–5% (5%NH₃/MeOH)/CH₂Cl₂] to furnish (2S,3S)-2-amino-3-hydroxy-*N*-*iso*butyl-*N*-methyl-butanamide in 49% (93.2 mg) yield over two steps. ¹H NMR (400 MHz, CDCl₃): δ 3.89–3.76 (m, 1H), 3.67 and 3.64 (two doublets, *J* = 4.7 Hz, 4.6 Hz, 1H), 3.36 (dd, *J* = 13.2, 8.0 Hz, 0.5H), 3.19 (dd, *J* = 14.4, 8.3 Hz, 0.5H), 3.10 (dd, *J* = 14.3, 7.0 Hz, 0.5H), 3.05 (s, 1.7H), 3.03–2.98 (m, 0.5H), 2.91 (s, 1.3H), 2.51 (brs, 3H), 2.00–1.87 (m, 1H), 1.10 (two doublets, *J* = 6.3, 6.3 Hz, 3H), 0.93–0.81 (m, 6H).

Compound **12d** was synthesized from (2S,3S)-2-amino-3-hydroxy-*N-iso*butyl-*N*-methyl-butanamide by reductive amination with aldehyde **11** following a similar procedure described for the synthesis of compound **12a** (yield 30%). ¹H NMR (300 MHz, CDCl₃): δ 7.33– 7.10 (m, 5H), 4.80–4.64 (m, 1H), 3.95–3.78 (m, 2H), 3.43 (dd, *J* = 11.8, 4.4 Hz, 1H), 3.35–3.09 (m, 2H), 3.06–2.96 (m, 2.5H), 2.91 (s, 1.5H), 2.84 (brs, 2H), 2.72–2.59 (m, 1H), 2.48–2.33 (m, 1H), 2.01– 1.87 (m, 1H), 1.39 (s, 9H), 1.10 and 1.06 (two doublets, *J* = 6.4, 6.4 Hz, 3H), 0.90 and 0.86 (two doublets, *J* = 6.7, 6.3 Hz, 6H).

Synthesis of Inhibitor 7. Inhibitor 7 was synthesized from compound 12d by Boc removal using trifluoroacetic acid followed by coupling of the resulting amine with the known acid 13 using EDC, HOBt, and 'Pr₂NEt following a similar procedure described for the synthesis of inhibitor 4 (yield 61%, over two steps). ¹H NMR (400 MHz, CDCl₃): δ 8.21 and 8.17 (two singlets, 1H), 8.07–7.92 (m, 2H), 7.45–7.30 (m, 4H), 7.30–7.15 (m, 6H), 7.07 (t, J = 7.8 Hz, 1H), 5.40–5.26 (m, 1H), 4.34–4.19 (m, 1H), 3.97–3.82 (m, 1H), 3.55 and 3.53 (two doublets, J = 4.2, 4.2 Hz, 1H), 3.33 (s, 3H), 3.23–3.03 (m, 2.5H), 3.01 (s, 2H), 2.95–2.87 (m, 1H), 2.85 and 2.84 (two singlets, 3H), 2.77 (s, 1H), 2.73–2.57 (m, 2.5H), 1.96–1.78 (m, 1H), 1.60 (d, J = 6.9 Hz, 3H), 1.13 and 1.10 (two doublets, J = 6.4, 6.5 Hz, 3H), 0.89 and 0.84 (two doublets, J = 6.6, 6.5 Hz, 2.7H), 0.79 and 0.75 (two doublets, J = 6.7, 6.7 Hz, 3.3H). HRMS-ESI (m/z): [M + H]⁺ calcd for C₃₆H₅₀N₅O₆S, 680.3482; found, 680.3478.

Synthesis of (25,35)-2-[(tert-Butoxycarbonyl)amino]-3-methoxybutanoic Acid (15). To a solution of (25,35)-methyl 2-[(tertbutoxycarbonyl)amino]-3-hydroxybutanoate (14) (2.14 mmol, 0.5 g) in CH₃CN (21 mL) were added Ag₂O (10.7 mmol, 2.48 g) and MeI (21.4 mmol, 1.3 mL) at 23 °C, and the resulting reaction mixture was stirred for 8 days at 23 °C. The reaction mixture was filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (20–25% EtOAc/hexanes) to furnish (2*S*,3*S*)-methyl 2-[(*tert*-butoxycarbonyl)amino]-3-methoxybutanoate in 55% yield (0.29 g). ¹H NMR (400 MHz, CDCl₃): δ 5.27 (d, J = 9.3 Hz, 1H), 4.41 (dd, J = 8.6, 3.6 Hz, 1H), 3.74 (s, 3H), 3.66– 3.55 (m, 1H), 3.34 (s, 3H), 1.43 (s, 9H), 1.18 (d, J = 6.4 Hz, 3H).

To a solution of (2S,3S)-methyl 2-[(*tert*-butoxycarbonyl)amino]-3methoxybutanoate (0.86 mmol, 0.213 g) in THF (4 mL) and H₂O (2 mL) was added LiOH.H₂O (5.16 mmol, 0.216 g) at 23 °C. The resulting reaction mixture was stirred for 5 h at 23 °C. The reaction mixture was diluted with H₂O and diethyl ether. The organic layer was separated, and the aqueous layer was carefully acidified with 2 N HCl and extracted with ethyl acetate. The combined extracts were dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure to provide crude (2S,3S)-2-[(*tert*-butoxycarbonyl)amino]-3methoxybutanoic acid (15). This crude acid was used in the coupling reaction without any further purification.

Synthesis of Compound **12e**. The synthesis of tert-butyl [(2S,3S)-1-(*iso*butylamino)-3-methoxy-1-oxobutan-2-yl]carbamate has been carried out by coupling of the above crude acid **15** with isobutyl amine using EDC, HOBt, and ⁱPr₂NEt following the procedure described for the synthesis of (S)-tert-butyl [1-(*iso*butylamino)-1-oxobutan-2-yl]carbamate (yield 74%, over two steps). ⁱH NMR (300 MHz, CDCl₃): δ 6.22 (brs, 1H), 5.15 (brs, 1H), 4.10 (dd, *J* = 7.7, 6.8 Hz, 1H), 3.59 (p, *J* = 6.4 Hz, 1H), 3.34 (s, 3H), 3.21–3.10 (m, 1H),

 $3.09{-}2.98$ (m, 1H), 1.77 (hept, J = 6.7 Hz, 1H), 1.44 (s, 9H), 1.18 (d, J = 6.3 Hz, 3H), 0.91 (d, J = 6.8 Hz, 6H).

To a solution of *tert*-butyl [$(2S_3S)$ -1-(*iso*butylamino)-3-methoxy-1oxobutan-2-yl]-carbamate (0.624 mmol, 0.18 g) in CH₂Cl₂ (6 mL) was added trifluoroacetic acid (2 mL) at 0 °C, and the resulting mixture was stirred for 1.5 h at 23 °C. Trifluoroacetic acid and CH₂Cl₂ were removed under reduced pressure, and the resulting residue was diluted with EtOAc and basified with saturated aqueous NaHCO₃ solution. The organic layer was separated, and the aqueous layer was extracted several times with EtOAc. The combined organic layers were dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure to obtain crude ($2S_3S$)-2-amino-N-isobutyl-3methoxybutanamide in 88% yield.

To a solution of the above crude amine (0.55 mmol, 0.104 g) and (S)-tert-butyl (1-oxo-3-phenylpropan-2-yl)carbamate 11 [prepared from the corresponding Weinreb amide (0.55 mmol) following a similar literature procedure]⁷ in CH_2Cl_2 (6 mL), Na(OAc)₃BH (0.825 mmol, 0.175 g) was added at 0 °C. The resulting mixture was stirred for 1 h at 0 °C and 15 h at 23 °C. The reaction mixture was quenched with saturated aqueous NaHCO₃ solution and extracted with CH₂Cl₂. The combined extracts were dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (20-45% EtOAc/hexanes) to furnish the corresponding adduct 12e in 67% yield (0.155 g). ¹H NMR (400 MHz, CDCl₃): δ 7.35 (brs, 1H), 7.29-7.21 (m, 2H), 7.21-7.10 (m, 3H), 4.64 (d, J = 8.2 Hz, 1H), 3.94 (brs, 1H), 3.77-3.68 (m, 1H), 3.29 (s, 3H), 3.27 (d, J = 4.0 Hz, 1H), 3.00 (t, J = 6.4Hz, 2H), 2.82 (dd, J = 12.9, 5.7 Hz, 1H), 2.69 (dd, J = 13.6, 7.7 Hz, 1H), 2.58-2.46 (m, 2H), 1.68 (hept, J = 6.7 Hz, 1H), 1.39 (s, 9H), 1.00 (d, J = 6.4 Hz, 3H), 0.83 (d, J = 6.6 Hz, 6H).

Synthesis of Inhibitor 8. To a solution of 12e (0.073 mmol, 30.8 mg) in CH_2Cl_2 (3 mL) was added trifluoroacetic acid (1 mL) at 0 °C. The resulting reaction mixture was warmed to 23 °C and stirred for 1.5 h at 23 °C. The reaction mixture was concentrated under reduced pressure, and the resulting residue was used in the next step without any further purification.

To a solution of the above residue in CH₂Cl₂ (5 mL) were added ⁱPr₂NEt (0.1 mL), HOBt·H₂O (0.14 mmol, 18.9 mg), acid 13 (0.07 mmol, 26.3 mg), and EDC·HCl (0.14 mmol, 26.8 mg) simultaneously at 23 °C. The resulting reaction mixture was stirred for 17 h at 23 °C. The reaction mixture was quenched with saturated aqueous NaHCO₃ solution and extracted with CH2Cl2. The combined extracts were dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (2%MeOH/CH₂Cl₂) to obtain the inhibitor 8 in 67% yield (32.1 mg). ¹H NMR (400 MHz, CDCl₃): δ 8.19 (s, 1H), 8.02 (s, 1H), 7.96 (s, 1H), 7.42–7.29 (m, 5H), 7.28–7.25 (m, 2H), 7.22 (d, J = 7.4 Hz, 3H), 7.14–7.02 (m, 3H), 5.32 (p, J = 7.2 Hz, 1H), 4.48–4.36 (m, 1H), 3.73–3.61 (m, 1H), 3.33 (s, 3H), 3.30 (s, 3H), 3.27 (d, J = 4.2 Hz, 1H), 3.04–2.94 (m, 3H), 2.90–2.80 (m, 4H), 2.76–2.65 (m, 2H), 1.69–1.61 (m, 1H), 1.61 (d, J = 6.9 Hz, 3H), 1.04 (d, J = 6.4 Hz, 3H), 0.80 (d, J = 6.4 Hz, 6H). ¹³C NMR (125 MHz, CDCl₃): δ 171.84, 165.41, 164.41, 142.87, 142.20, 137.42, 135.67, 135.64, 129.11, 128.60, 128.57, 127.80, 127.73, 127.38, 126.63, 126.18, 123.41, 65.95, 56.52, 51.99, 51.19, 49.53, 46.33, 38.73, 37.83, 35.43, 28.32, 21.63, 20.00, 14.62. HRMS-ESI (m/z): $[M + H]^+$ calcd for $C_{36}H_{50}N_5O_6S_7$ 680.3482; found, 680.3488.

Synthesis of tert-Butyl {(2R,3S)-3-[(tert-Butyldimethylsilyl)oxy]-1-(isobutylamino)butan-2-yl}carbamate (16). To a solution of (2S,3S)-methyl 2-[(tert-butoxycarbonyl)amino]-3-hydroxybutanoate (14) (2.2 mmol, 0.513 g) in CH₂Cl₂ (11 mL) were added Et₃N (3.3 mmol, 0.46 mL) and TBSOTf (2.86 mmol, 0.66 mL) at 0 °C. The resulting reaction mixture was warmed to 23 °C and stirred for 2 h at the same temperature. The reaction mixture was diluted with H₂O and CH₂Cl₂. The organic layer was separated, and the aqueous layer was extracted with CH₂Cl₂. The combined extracts were dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (10% EtOAc/hexanes) to obtain (2S,3S)-methyl 2-[(tert-butoxycarbonyl)amino]-3-[(tert-butyldimethylsilyl)oxy]butanoate in 88% yield (0.67 g). ¹H NMR (400 MHz, CDCl₃): δ 5.25 (d, *J* = 8.4 Hz, 1H), 4.16 (dd, *J* = 8.3, 3.7 Hz, 1H), 4.05–3.96 (m, 1H), 3.66 (s, 3H), 1.36 (s, 9H), 1.16 (d, *J* = 6.3 Hz, 3H), 0.79 (s, 9H), -0.03 (s, 6H).

To a solution of (2S,3S)-methyl 2-[(*tert*-butoxycarbonyl)amino]-3-[(*tert*-butyldimethyl-silyl)oxy]butanoate (0.288 mmol, 0.1 g) in Et₂O (3 mL) was added DiBAL-H (0.63 mmol, 0.63 mL, 1 M solution in CH₂Cl₂) at -78 °C, and the resulting mixture was stirred for 1.5 h at -78 °C. The reaction mixture was quenched with 0.5 mL of EtOAc and diluted with Et₂O and saturated aqueous sodium potassium tartrate. After it was stirred for 0.5 h, the organic layer was separated, and the aqueous layer was extracted with Et₂O. The combine extracts were washed with brine, dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure. The resulting residue was used in the next step without any further purification.

To a solution of the above aldehyde in CH_2Cl_2 (6 mL) were added isobutyl amine (0.864 mmol, 0.086 mL) and Na(OAc)₃BH (0.576 mmol, 0.122 g) at 0 °C, and the resulting reaction mixture was stirred for 1.5 h at 0 °C and 15 h at 23 °C. The reaction mixture was quenched with saturated aqueous NaHCO₃ solution and extracted with CH_2Cl_2 . The combined extracts were dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography [3% (5%NH₃/MeOH)/CH₂Cl₂] to obtain (*tert*-butyl {(2*R*,3*S*)-3-[(*tert*-butyldimethylsilyl)oxy]-1-(*iso*butylamino)butan-2-yl}-carbamate (16) in 75% yield (80.7 mg). ¹H NMR (400 MHz, CDCl₃): δ 5.36 (d, *J* = 7.9 Hz, 1H), 4.11–3.98 (m, 1H), 3.57–3.42 (m, 1H), 2.90 (dd, *J* = 12.2, 5.3 Hz, 1H), 2.62 (dd, *J* = 12.2, 4.3 Hz, 1H), 2.44–2.30 (m, 2H), 1.72 (hept, *J* = 6.7 Hz, 1H), 1.43 (s, 9H), 1.14 (d, *J* = 6.4 Hz, 3H), 0.92–0.84 (m, 15H), 0.04 (s, 3H), 0.03 (s, 3H).

Synthesis of Compound 17. Compound 17 was synthesized by Boc removal of *tert*-butyl {(2R,3S)-3-[(*tert*-butyldimethylsilyl)oxy]-1-(*iso*butylamino)butan-2-yl}carbamate (16) using trifluoroacetic acid followed by reductive amination with known aldehyde 11 following the procedure described for the synthesis of 12e. ¹H NMR (400 MHz, CDCl₃): δ 7.31–7.23 (m, 2H), 7.23–7.15 (m, 3H), 5.20 (brs, 1H), 3.94–3.75 (m, 2H), 2.95–2.81 (m, 1H), 2.79–2.67 (m, 2H), 2.58 (dd, *J* = 12.4, 5.0 Hz, 2H), 2.50–2.43 (m, 2H), 2.38 (qd, *J* = 11.5, 6.9 Hz, 2H), 1.74 (hept, *J* = 6.7 Hz, 1H), 1.40 (s, 9H), 1.10 (d, *J* = 6.3 Hz, 3H), 0.90 (d, *J* = 6.6 Hz, 6H), 0.87 (s, 9H), 0.04 (s, 3H), 0.02 (s, 3H).

Synthesis of Inhibitor **9**. Boc removal of compound 17 using trifluoroacetic acid followed by coupling of the resulting amine with known acid **13** using EDC, HOBt, and ⁱPr₂NEt following the procedure described for the synthesis of inhibitor **8** afforded the corresponding amide in 70% yield. ¹H NMR (400 MHz, CDCl₃): δ 8.20 (s, 1H), 8.00 (s, 1H), 7.94 (d, J = 7.8 Hz, 1H), 7.92 (s, 1H), 7.66 (d, J = 7.6 Hz, 1H), 7.40 (d, J = 7.5 Hz, 2H), 7.33 (t, J = 7.5 Hz, 2H), 7.29–7.19 (m, 5H), 7.20–7.12 (m, 1H), 5.29 (p, J = 7.1 Hz, 1H), 4.20–4.06 (m, 1H), 4.06–3.93 (m, 1H), 3.28 (s, 3H), 3.20 (dd, J = 12.4, 8.2 Hz, 1H), 3.10–2.98 (m, 2H), 2.86 (dd, J = 13.6, 6.4 Hz, 1H), 2.82–2.76 (m, 4H), 2.76–2.67 (m, 3H), 2.60 (dd, J = 12.4, 7.1 Hz, 1H), 1.81 (hept, J = 6.8 Hz, 1H), 1.59 (d, J = 7.0 Hz, 3H), 1.11 (d, J = 6.4 Hz, 3H), 0.86 (s, 9H), 0.75 (d, J = 6.7 Hz, 3H), 0.75 (d, J = 6.7 Hz, 3H), 0.07 (s, 3H), 0.05 (s, 3H).

To a solution of the above amide (0.104 mmol, 79.7 mg) in THF (10 mL) was added TBAF (1.25 mmol, 1.25 mL, 1 M solution in THF) at 0 °C, and the resulting reaction mixture was stirred for 18 h at 23 °C. The solvent was removed under reduced pressure, and the resulting residue was purified by silica gel column chromatography $[3-5\% (5\% NH_3/MeOH)/CH_2Cl_2]$ to obtain inhibitor 9 in 65% (43.9 mg) yield. ¹H NMR (400 MHz, CDCl₃): δ 8.24 (s, 1H), 8.01-7.93 (m, 2H), 7.40 (d, J = 7.3 Hz, 2H), 7.37–7.24 (m, 7H), 7.24–7.16 (m, 3H), 5.31 (p, J = 7.3 Hz, 1H), 4.37-4.25 (m, 1H), 3.93-3.83 (m, 1H), 3.31 (s, 3H), 3.04 (dd, J = 13.5, 5.8 Hz, 1H), 2.81 (s, 3H), 2.80-2.67 (m, 5H), 2.44-2.27 (m, 3H), 1.70-1.54 (m, 4H), 1.13 (d, J = 6.8 Hz, 3H), 0.81 (d, J = 6.5 Hz, 6H). ¹³C NMR (100 MHz, CDCl₃): δ 165.78, 164.64, 143.13, 142.13, 137.87, 135.80, 129.24, 128.63, 128.53, 128.16, 127.46, 127.37, 126.53, 126.34, 123.78, 68.48, 60.61, 57.62, 51.94, 49.74, 49.48, 49.30, 38.67, 37.88, 35.46, 27.73, 21.78, 20.41, 20.38, 20.34. HRMS-ESI (m/z): $[M + H]^+$ calcd for $C_{35}H_{50}N_5O_5S_7$ 652.3533; found, 652.3543.

Synthesis of Inhibitor 18. Inhibitor 18 was synthesized from compound 12b by Boc removal using trifluoroacetic acid followed by coupling of the resulting amine with known acid 23 using EDC, HOBt, and ⁱPr₂NEt following a similar procedure described for the synthesis of inhibitor 4 (yield 68%, over two steps). ¹H NMR (400 MHz, CDCl₃): δ 7.85 (s, 1H), 7.47 (s, 1H), 7.38–7.28 (m, 3H), 7.24– 7.19 (m, 2H), 6.84 (s, 1H), 6.47 (d, J = 8.0 Hz, 1H), 4.62–4.36 (m, 3H), 4.02 (p, J = 6.0 Hz, 1H), 3.90-3.81 (m, 2H), 3.47 (s, 3H), 3.12(d, J = 5.0 Hz, 1H), 3.10-2.93 (m, 4H), 2.84 (dd, J = 12.2, 4.7 Hz,1H), 2.77 (dd, J = 11.1, 6.8 Hz, 1H), 2.72 (q, J = 7.5 Hz, 2H), 1.76-1.65 (m, 1H), 1.30 (t, J = 7.5 Hz, 3H), 1.15 (d, J = 6.4 Hz, 3H), 0.85 (d, J = 6.7 Hz, 3H), 0.84 (d, J = 6.6 Hz, 3H). ¹³C NMR (100 MHz, $CDCl_3$): δ 172.75, 167.90, 137.52, 133.84, 130.72, 129.28, 128.65, 127.72, 127.23, 126.75, 125.78, 120.26, 118.03, 117.60, 68.32, 67.48, 56.77, 52.30, 51.39, 46.41, 43.60, 39.66, 39.03, 28.42, 20.11, 18.95, 17.93, 14.25. HRMS-ESI (m/z): $[M + H]^+$ calcd for $C_{31}H_{44}N_5O_5S_7$ 598.3063; found, 598.3060.

Synthesis of Compound **25**. To a solution of **24** (0.43 mmol, 0.145 g) in DMF (4 mL) was added NaH (1.72 mmol, 68.8 mg, 60% NaH in mineral oil) at 23 °C, and the resulting mixture was stirred for 15 min at the same temperature. Iodomethane (1.72 mmol, 0.11 mL) was added to the reaction mixture, and stirring was continued for further 2.5 h at 23 °C. The reaction mixture was quenched with methanol and then diluted with EtOAc. The resulting solution was washed with H₂O and brine, dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (30% EtOAc/hexanes) to obtain the corresponding α,α -dimethylated adduct in 51% (76.8 mg) yield. ¹H NMR (400 MHz, CDCl₃): δ 8.18 (d, *J* = 1.0 Hz, 1H), 7.74 (s, 1H), 6.81 (s, 1H), 4.14 (s, 2H), 3.93 (s, 3H), 3.55 (s, 3H), 2.76 (q, *J* = 7.5 Hz, 2H), 1.57 (s, 6H), 1.32 (t, *J* = 7.5 Hz, 3H).

A mixture of the above ester (0.219 mmol, 76.7 mg) and NaOH (20 mmol, 10 mL, 2 N NaOH) in EtOH (10 mL) and THF (10 mL) was stirred for 2.5 days at 23 °C. The solvent was removed under reduced pressure, and the resulting mixture was diluted with H₂O and diethyl ether. The organic layer was separated, and the aqueous layer was acidified with aqueous 1 N HCl and extracted with ethyl acetate. The combined extracts were dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure to furnish the corresponding crude acid (25) in 72% yield (53.2 mg), which was used directly in the coupling reaction without any further purification. LRMS-ESI (m/z): [M + Na]⁺, 359.19

Synthesis of 1-(Benzyloxymethyl)cyclopropanesulfonyl Chloride (27). Solutions of BuLi [17.2 mmol, 6.9 mL (2.5 M in hexanes) in 15 mL of THF] and butyl 3-chloro-1-propanesulfonate (26) (16.3 mmol, 3.5 g in 15 mL of THF) were added at the same time via cannula to an oven-dried flask containing THF (100 mL) at -78 °C, and the resulting mixture was stirred for 5–10 min at -78 °C and 30 min at 0 $^{\circ}$ C. The reaction mixture was cooled back to -78 $^{\circ}$ C, and a solution of BuLi [19.6 mmol, 7.8 mL (2.5 M in hexanes)] was added to this mixture. After it was stirred for 15 min at -78 °C, BOMCl (19.6 mmol, 2.7 mL) was added to the reaction flask, and stirring was continued for further 2 h at -78 °C and 3 h at 23 °C. The reaction mixture was quenched with H2O, and THF was removed under reduced pressure. The resulting mixture was diluted with CH2Cl2 and H₂O. The organic layer was separated, and the aqueous layer was extracted with CH2Cl2. The combined extracts were dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (8–12% EtOAc/hexanes) to furnish butyl 1-(benzyloxymethyl)cyclopropanesulfonate in 80% yield (3.9 g). ¹H NMR (300 MHz, $CDCl_3$): δ 7.40–7.25 (m, 5H), 4.55 (s, 2H), 4.23 (t, J = 6.6 Hz, 2H), 3.79 (s, 2H), 1.73–1.58 (m, 2H), 1.48 (ABq, J = 6.9, 5.0 Hz, 2H), 1.44–1.30 (m, 2H), 1.11 (ABq, J = 7.0, 5.1 Hz, 2H), 0.90 (t, J = 7.4 Hz, 3H). ¹³C NMR (75 MHz, CDCl₃): δ 137.41, 128.33, 127.78, 127.61, 73.09, 70.66, 69.84, 37.81, 31.04, 18.55, 13.41, 10.72.

To a mixture of butyl 1-(benzyloxymethyl)cyclopropanesulfonate (13 mmol, 3.88 g) in DME (40 mL) and H_2O (40 mL), KSCN (13.65 mmol, 1.33 g) was added at 23 °C, and the resulting reaction mixture was refluxed for 15 h. The reaction mixture was cooled to 23 °C and

diluted with H_2O and ethyl acetate. The organic layer was separated, and the aqueous layer was concentrated under reduced pressure to provide the crude potassium 1-(benzyloxymethyl)cyclopropanesulfonate, which was used directly in the next step without additional purification.

A mixture of potassium 1-(benzyloxymethyl)cyclopropanesulfonate in SOCl₂ (35 mL) and DMF (3.5 mL) was refluxed for 1.5 h, and excess SOCl₂ was removed under reduced pressure. Water was added carefully to the resulting mixture and extracted with ethyl acetate. The combined extracts were dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (5–10% EtOAc/hexanes) to obtain 1-(benzyloxymethyl)cyclopropanesulfonyl chloride **27** in 91% yield (3.1 g) (over two steps). ¹H NMR (300 MHz, CDCl₃): δ 7.46–7.28 (m, SH), 4.63 (s, 2H), 4.01 (s, 2H), 1.85–1.77 (m, 2H), 1.46–1.37 (m, 2H). ¹³C NMR (75 MHz, CDCl₃): δ 136.99, 128.41, 127.89, 127.61, 73.29, 68.38, 52.39, 14.03.

Synthesis of Sulfonamide 29. To a mixture of amine 28 (3.66 mmol, 0.8 g), pyridine (11 mmol, 0.89 mL), and DMAP (0.73 mmol, 89.2 mg) in CH_2Cl_2 at 0 °C was added a solution of 1-(benzyloxymethyl)-cyclopropanesulfonyl chloride (27) (3.84 mmol, 1 g in 5 mL of CH_2Cl_2), and the resulting mixture was stirred for 44 h at 23 °C. The reaction mixture was diluted with CH₂Cl₂, washed with aqueous 1 N HCl and brine, and dried over anhydrous Na2SO4. Dichloromethane solution was filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (20-30% EtOAc/hexanes) to afford the corresponding sulfonamide 29 in 74% yield (1.2 g). ¹H NMR (400 MHz, $CDCl_3$): δ 9.38 (s, 1H), 8.25 (s, 1H), 7.87 (s, 1H), 7.49 (d, J = 7.1 Hz, 2H), 7.42 (t, J = 7.4 Hz, 2H), 7.39-7.33 (m, 1H), 6.79 (s, 1H), 6.69 (s, 1H), 4.73 (s, 2H), 3.91 (s, 3H), 3.90 (s, 2H), 2.75 (q, J = 7.5 Hz, 2H), 1.30 (t, J = 7.5 Hz, 3H), 1.11–0.99 (m, 2H), 0.77–0.65 (m, 2H). ^{13}C NMR (100 MHz, CDCl₃): δ 167.62, 136.35, 135.01, 128.91, 128.63, 128.44, 122.14, 121.20, 120.85, 120.76, 120.61, 120.36, 74.15, 73.10, 51.84, 38.91, 18.09, 14.25, 10.25.

Synthesis of 7,6,5-Tricyclic Indole Derivative **30**. To a solution of sulfonamide **29** (2.7 mmol, 1.19 g) in MeOH (75 mL) and AcOH (25 mL), 10% Pd/C (0.2 g) was added under argon. The argon balloon was now replaced with a H_2 balloon, and the resulting mixture was stirred for 16 h at 23 °C. The reaction mixture was filtered through Celite and washed with MeOH. The solvent was removed under reduced pressure, and the resulting residue was diluted with toluene and concentrated under reduced pressure to furnish the corresponding alcohol in 95% yield.

To a mixture of the above alcohol (0.6 mmol, 0.21 g) and Et₃N (0.9 mmol, 0.12 mL) in CH₂Cl₂ (25 mL) at 0 °C was added methanesulfonyl chloride (0.63 mmol, 0.049 mL), and the resulting mixture was stirred for 2 h at 23 °C. The reaction mixture was diluted with CH₂Cl₂, washed with aqueous 1 N HCl and brine, and dried over anhydrous Na₂SO₄. Dichloromethane solution was filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (5–15% diethyl ether/CH₂Cl₂) to afford the corresponding mesylate in 46% (70% BRSM) yield (0.12 g, 69 mg of alcohol was recovered). ¹H NMR (400 MHz, CDCl₃): δ 9.24 (s, 1H), 8.26 (s, 1H), 7.87 (d, *J* = 1.0 Hz, 1H), 7.41 (s, 1H), 7.07 (s, 1H), 4.58 (s, 2H), 3.93 (s, 3H), 3.16 (s, 3H), 2.79 (q, *J* = 7.5 Hz, 2H), 1.38–1.28 (m, 5H), 1.06–0.97 (m, 2H).

To a solution of the above mesylate (0.69 mmol, 0.297 g) in DMF (30 mL) was added NaH (2.76 mmol, 0.11 g, 60% dispersion in mineral oil) at 23 °C. After the mixture was stirred for 3 h at 23 °C, iodomethane (3.5 mmol, 0.22 mL) was added to the flask, and stirring was continued for further 1 h at 23 °C. The reaction mixture was carefully quenched with MeOH, diluted with ethyl acetate, and washed with aqueous 1 N HCl. The ethyl acetate solution was filtered and concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (35–40% EtOAc/ hexanes) to afford the corresponding 7,6,5-tricyclic indole derivative in 87% yield (0.21 g). ¹H NMR (400 MHz, CDCl₃): δ 8.26 (d, *J* = 1.1 Hz, 1H), 7.83 (d, *J* = 1.0 Hz, 1H), 6.78 (s, 1H), 4.32 (s, 2H), 3.93 (s,

3H), 3.48 (s, 3H), 2.77 (q, J = 7.5 Hz, 2H), 1.53 (t, J = 6.6 Hz, 2H), 1.31 (t, J = 7.5 Hz, 3H), 1.03–0.95 (m, 2H).

A mixture of the above 7,6,5-tricyclic indole derivative (0.2 mmol, 69.7 mg) and NaOH (20 mmol, 0.8 g in 10 mL of H_2O) in EtOH (5 mL) and THF (10 mL) was stirred for 4 days at 23 °C. The solvent was removed under reduced pressure, and the resulting mixture was diluted with H_2O and diethyl ether. The organic layer was separated, and the aqueous layer was acidified with aqueous 1 N HCl and extracted with ethyl acetate. The combined extracts were dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure to furnish the corresponding crude acid (**30**) in 75% yield (50 mg), which was used directly in the coupling reaction without any further purification. LRMS-ESI (m/z): [M + Na]⁺, 357.26

Synthesis of (2R,3S)-Ethyl 3-Hydroxy-2-{[(4-nitrophenyl)sulfonyl]oxy}hexanoate (32). To a solution of (E)-ethyl hex-2-enoate (31) (12.6 mmol, 1.79 g) in 'BuOH (30 mL) and H₂O (30 mL) were added AD-mix α (17.6 g) and MeSO₂NH₂ (15.1 mmol, 1.44 g) at -1 °C, and the resulting reaction mixture was stirred for 7 days at -1 °C. The reaction mixture was quenched with saturated aqueous Na₂S₂O₃ solution and extracted with ethyl acetate. The combined extracts were dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (20–35% EtOAc/hexanes) to furnish (2R,3S)-ethyl 2,3-dihydroxyhexanoate in 60% yield (1.34 g). ¹H NMR (300 MHz, CDCl₃): δ 4.29 (q, J = 7.2 Hz, 2H), 4.10–4.04 (m, 1H), 3.96–3.84 (m, 1H), 3.07 (d, J = 5.2 Hz, 1H), 1.90 (d, J = 7.7 Hz, 1H), 1.68–1.38 (m, 4H), 1.32 (t, J = 7.1 Hz, 3H), 0.96 (t, J = 7.2 Hz, 3H).

To a solution of (2R,3S)-ethyl 2,3-dihydroxyhexanoate (6.7 mmol, 1.18 g) in CH_2Cl_2 (30 mL) were added Et_3N (10 mmol, 1.39 mL) and 4-nitrobenzenesulfonyl chloride (6.7 mmol, 1.48 g) at 0 °C. The resulting reaction mixture was stirred for 24 h at 23 °C. The reaction mixture was diluted with H2O and CH2Cl2. The organic layer was separated, and the aqueous layer was extracted with CH₂Cl₂. The combined extracts were dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (10-25% EtOAc/hexanes) to obtain (2R,3S)-ethyl 3-hydroxy-2-{[(4-nitrophenyl)sulfonyl]oxy}hexanoate (32) in 54% yield (1.3 g). ¹H NMR (400 MHz, CDCl₃): δ 8.38 (d, J = 8.8 Hz, 2H), 8.16 (d, J = 8.9 Hz, 2H), 4.96 (d, J = 2.9 Hz, 1H), 4.15 (q, J = 7.1 Hz, 2H), 4.12–4.04 (m, 1H), 2.07 (brs, 1H), 1.62–1.44 (m, 3H), 1.43–1.30 (m, 1H), 1.21 (t, J = 7.1 Hz, 3H), 0.92 (t, J = 7.0 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃): δ 166.74, 150.75, 141.85, 129.45, 124.18, 80.97, 71.23, 62.30, 34.98, 18.47, 13.89, 13.63.

Synthesis of (25,35)-Ethyl 2-[(tert-Butoxycarbonyl)amino]-3hydroxyhexanoate (33). To a solution of (2R,3S)-ethyl 3-hydroxy-2-{[(4-nitrophenyl)sulfonyl]oxy}hexanoate (32) (3.6 mmol, 1.3 g) in DMF (10 mL), NaN₃ (5.76 mmol, 0.374 g) was added at 23 °C, and the resulting mixture was heated at 55 °C for 15 h. The reaction mixture was cooled to 23 °C and diluted with ethyl acetate, and the resulting solution was washed with H₂O, dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (15% EtOAc/hexanes) to obtain (2S,3S)-ethyl 2-azido-3-hydroxyhexanoate in 83% yield (0.6 g). ¹H NMR (400 MHz, CDCl₃): δ 4.29 (qd, J = 7.2, 1.3 Hz, 2H), 3.94 (s, 2H), 2.32 (brs, 1H), 1.59–1.45 (m, 3H), 1.44– 1.37 (m, 1H), 1.33 (t, J = 7.2 Hz, 3H), 0.94 (t, J = 6.9 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃): δ 168.92, 71.56, 66.15, 61.99, 35.03, 18.52, 14.06, 13.74.

To a mixture of (2S,3S)-ethyl 2-azido-3-hydroxyhexanoate (2.98 mmol, 0.6 g) and $(Boc)_2O$ (4.47 mmol, 0.975 g) in EtOH (15 mL) was added 10% Pd–C (0.15 g) at 23 °C under argon. The argon balloon was replaced with a H₂ balloon, and the reaction mixture was stirred for 15 h under H₂ atmosphere. The reaction mixture was filtered through Celite, washed with ethyl acetate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (10–25% EtOAc/hexanes) to obtain (2S,3S)-ethyl 2-[(*tert*-butoxycarbonyl)amino]-3-hydroxyhexanoate (33) in 96% yield (0.79 g). ¹H NMR (300 MHz, CDCl₃): δ 5.52 (d, J = 7.2 Hz, 1H), 4.42–4.28 (m, 1H), 4.27–4.13 (m, 2H), 3.94–3.80 (m, 1H), 3.03 (brs, 1H), 1.59–1.30 (m, 13H), 1.26 (t, J = 7.1 Hz, 3H), 0.89 (t, J =

6.9 Hz, 3H). ¹³C NMR (75 MHz, CDCl₃): δ 170.68, 155.98, 80.20, 72.67, 61.48, 58.34, 35.29, 28.18, 18.86, 14.06, 13.82. LRMS-ESI (*m*/*z*): [M + Na]⁺, 298.26.

Synthesis of tert-Butyl [(25,35)-3-Hydroxy-1-(isobutylamino)-1oxohexan-2-yl]carbamate (**34a**). To a solution of (25,35)-ethyl 2-[(tert-butoxycarbonyl)amino]-3-hydroxyhexanoate (**33**) (0.67 mmol, 0.18 g) in THF (6 mL) and H₂O (3 mL) was added LiOH·H₂O (3.45 mmol, 0.145 g). The resulting reaction mixture was stirred for 12 h at 23 °C. The reaction mixture was diluted with H₂O and ethyl acetate. The organic layer was separated, and the aqueous layer was acidified with 1 N HCl and extracted with ethyl acetate. The combined extracts were dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure. The residue was used in the coupling reaction without any further purification.

The synthesis of *tert*-butyl [(2*S*,3*S*)-3-hydroxy-1-(*iso*butylamino)-1oxohexan-2-yl]carbamate (**34a**) has been carried out by coupling of (2*S*,3*S*)-2-[(*tert*-butoxycarbonyl)amino]-3-hydroxyhexanoic acid with isobutyl amine using EDC, HOBt, and ⁱPr₂NEt following a similar procedure described for the synthesis of (*S*)-*tert*-butyl [1-(*iso*butylamino)-1-oxobutan-2-yl]carbamate (yield 60%, over two steps). ¹H NMR (400 MHz, CDCl₃): δ 6.51 (brs, 1H), 5.62 (d, *J* = 7.2 Hz, 1H), 3.98–3.82 (m, 2H), 3.69 (brs, 1H), 3.21–3.08 (m, 1H), 3.06–2.92 (m, 1H), 1.77 (hept, *J* = 6.7 Hz, 1H), 1.63–1.46 (m, 3H), 1.44 (s, 9H), 1.41–1.32 (m, 1H), 0.97–0.83 (m, 9H).

Synthesis of Compound **35a**. Compound **35a** was synthesized from *tert*-butyl [(2*S*,3*S*)-3-hydroxy-1-(*iso*butylamino)-1-oxohexan-2-yl]carbamate (**34a**) by Boc removal using trifluoroacetic acid followed by reductive amination of the resulting amine with aldehyde **11** following the procedure described for the synthesis of compound **12a** (yield 49%, over two steps). ¹H NMR (400 MHz, CDCl₃): δ 7.28 (t, *J* = 7.2 Hz, 2H), 7.22 (d, *J* = 7.0 Hz, 1H), 7.19–7.13 (m, 2H), 4.63 (d, *J* = 7.4 Hz, 1H), 3.92 (brs, 1H), 3.84–3.74 (m, 1H), 3.12–2.94 (m, 3H), 2.86–2.71 (m, 2H), 2.64 (dd, *J* = 12.1, 4.6 Hz, 1H), 2.55 (dd, *J* = 12.0, 7.4 Hz, 1H), 1.71 (hept, *J* = 6.7 Hz, 1H), 1.58–1.21 (m, 13H), 0.90 (t, *J* = 7.0 Hz, 3H), 0.86 (d, *J* = 6.6 Hz, 6H).

Synthesis of Inhibitor 19. Inhibitor 19 has been synthesized from compound 35a by Boc removal using trifluoroacetic acid followed by coupling of the resulting amine with known acid 23 using EDC, HOBt, and Pr2NEt following a similar procedure described for the synthesis of inhibitor 8 (yield 50%). ¹H NMR (400 MHz, CDCl₃): δ 7.85 (d, J = 1.0 Hz, 1H), 7.46 (s, 1H), 7.35–7.28 (m, 2H), 7.26–7.19 (m, 3H), 6.84 (s, 1H), 6.41 (d, J = 8.2 Hz, 1H), 4.54-4.44 (m, 3H), 3.89-3.76 (m, 3H), 3.47 (s, 3H), 3.13 (d, J = 4.9 Hz, 1H), 3.11-2.99 (m, 2H), 2.97 (d, J = 6.8 Hz, 2H), 2.83 (dd, J = 12.3, 4.8 Hz, 1H), 2.79-2.68 (m, 3H), 1.71 (hept, J = 6.7 Hz, 1H), 1.54-1.33 (m, 4H), 1.30 (t, J = 7.5 Hz, 3H), 0.91–0.80 (m, 9H). ¹³C NMR (100 MHz, CDCl₃): δ 172.89, 167.85, 137.51, 133.83, 130.72, 129.30, 128.67, 127.72, 127.26, 126.78, 125.83, 120.25, 117.93, 117.56, 72.00, 66.43, 56.81, 51.98, 51.20, 46.44, 43.62, 39.61, 38.94, 35.26, 28.42, 20.10, 18.98, 17.94, 14.26, 13.94. HRMS-ESI (m/z): $[M + H]^+$ calcd for C33H48N5O5S, 626.3376; found, 626.3369.

Synthesis of Inhibitor 20. Inhibitor 20 has been synthesized from compound 35a by Boc removal using trifluoroacetic acid followed by coupling of the resulting amine with acid 25 using EDC, HOBt, and ⁱPr₂NEt following the similar procedure described for the synthesis of inhibitor 8 (yield 52%). ¹H NMR (400 MHz, CDCl₃): δ 7.71 (d, J = 0.8 Hz, 1H), 7.40 (s, 1H), 7.34-7.28 (m, 2H), 7.26-7.18 (m, 3H), 6.80 (s, 1H), 6.39 (d, J = 8.2 Hz, 1H), 4.54–4.40 (m, 1H), 4.11 (s, 2H), 3.80 (p, J = 4.2 Hz, 1H), 3.50 (s, 3H), 3.13 (d, J = 4.8 Hz, 1H), 3.11-2.99 (m, 2H), 2.97 (d, J = 6.8 Hz, 2H), 2.82 (dd, J = 12.3, 5.0 Hz, 1H), 2.79-2.64 (m, 3H), 1.70 (hept, J = 6.7 Hz, 1H), 1.56 (s, 6H), 1.53–1.33 (m, 4H), 1.30 (t, J = 7.5 Hz, 3H), 0.93–0.79 (m, 9H). ¹³C NMR (125 MHz, CDCl₃): δ 172.59, 167.99, 137.38, 134.28, 130.53, 129.22, 128.81, 128.59, 127.37, 126.83, 126.71, 120.29, 116.36, 114.86, 71.83, 66.29, 65.68, 56.50, 51.89, 51.03, 46.38, 39.40, 38.81, 35.15, 28.33, 22.49, 22.46, 20.03, 19.71, 18.90, 17.88, 14.02, 13.87. HRMS-ESI (m/z): $[M + H]^+$ calcd for $C_{35}H_{52}N_5O_5S$, 654.3689; found, 654.3696.

Synthesis of Inhibitor 21. Inhibitor 21 was synthesized (yield 65% over two steps) from 12b by Boc deprotection followed by coupling

with 7,6,5-tricyclic indole derivative **30** as described for the inhibitor 4. ¹H NMR (400 MHz, CDCl₃): δ 7.88 (s, 1H), 7.47 (s, 1H), 7.36 (t, *J* = 6.0 Hz, 1H), 7.33–7.27 (m, 2H), 7.26–7.17 (m, 3H), 6.77 (s, 1H), 6.55 (d, *J* = 8.2 Hz, 1H), 4.56–4.43 (m, 1H), 4.27 (s, 2H), 4.03 (p, *J* = 6.2 Hz, 1H), 3.41 (s, 3H), 3.12 (d, *J* = 5.1 Hz, 1H), 3.08–2.99 (m, 2H), 2.95 (dd, *J* = 6.5, 4.4 Hz, 2H), 2.82 (dd, *J* = 12.2, 4.7 Hz, 1H), 2.78–2.65 (m, 3H), 1.69 (hept, *J* = 6.6 Hz, 1H), 1.52 (t, *J* = 6.3 Hz, 2H), 1.28 (t, *J* = 7.5 Hz, 3H), 1.13 (d, *J* = 6.4 Hz, 3H), 1.00 (t, *J* = 6.4 Hz, 2H), 0.83 (d, *J* = 6.7 Hz, 3H), 0.82 (d, *J* = 6.6 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃): δ 172.75, 167.89, 137.56, 134.44, 130.80, 129.26, 128.62, 128.14, 127.09, 126.71, 126.13, 120.33, 118.15, 117.90, 68.26, 67.53, 52.30, 52.23, 51.39, 46.39, 43.05, 39.77, 39.02, 28.40, 20.09, 18.86, 17.94, 14.19, 12.67. HRMS-ESI (*m*/*z*): [M + H]⁺ calcd for C₃₃H₄₆N₅O₅S, 624.3220; found, 624.3223.

Synthesis of Compound **35b**. (2*S*,3*S*)-2-Amino-3-hydroxy-*N*isopropylhexanamide was synthesized from (2*S*, 3*S*)-2-[(*tert*butoxycarbonyl)amino]-3-hydroxyhexanoic acid by coupling with isopropyl amine using EDC, HOBt, and ⁱPr₂NEt followed by Boc removal using trifluoroacetic acid following the procedure described for the synthesis of (2*S*,3*S*)-2-amino-3-hydroxy-*N*-isobutyl-*N*-methylbutanamide (yield 79% over two steps). ¹H NMR (400 MHz, CDCl₃): δ 7.22 (brs, 1H), 4.14–3.92 (m, 1H), 3.81–3.67 (m, 1H), 3.22 (d, *J* = 6.2 Hz, 1H), 2.40 (brs, 2H), 1.62–1.24 (m, 4H), 1.18–1.08 (m, 6H), 0.91 (t, *J* = 6.9 Hz, 3H).

Compound **35b** was prepared from (2*S*,3*S*)-2-amino-3-hydroxy-*N*-isopropylhexanamide by reductive amination with aldehyde **11** following the procedure described for the synthesis of compound **12a** (yield 81%). ¹H NMR (400 MHz, CDCl₃): δ 7.28 (t, *J* = 7.4 Hz, 2H), 7.22 (d, *J* = 7.3 Hz, 1H), 7.20–7.13 (m, 2H), 7.00 (br, 1H), 4.62 (d, *J* = 8.1 Hz, 1H), 4.08–3.85 (m, 2H), 3.83–3.72 (m, 1H), 2.98 (d, *J* = 5.3 Hz, 1H), 2.82 (dd, *J* = 13.7, 6.5 Hz, 1H), 2.75 (dd, *J* = 13.3, 7.4 Hz, 1H), 2.60 (dd, *J* = 12.2, 4.7 Hz, 1H), 2.54 (dd, *J* = 12.1, 7.3 Hz, 1H), 1.59–1.20 (m, 13H), 1.11 (d, *J* = 6.5 Hz, 3H), 1.06 (d, *J* = 6.6 Hz, 3H), 0.90 (t, *J* = 7.0 Hz, 3H).

Synthesis of Inhibitor 22. Inhibitor 22 was synthesized by Boc removal of 35b using trifluoroacetic acid followed by coupling of the resulting amine with the acid 30 using EDC, HOBt, and Pr2NEt following a similar procedure described for the synthesis of inhibitor 4 (yield 65% over two steps). ¹H NMR (400 MHz, CDCl₃): δ 7.88 (d, J = 1.1 Hz, 1H), 7.46 (d, J = 1.0 Hz, 1H), 7.36-7.28 (m, 2H), 7.28-7.20 (m, 3H), 6.97 (d, J = 8.2 Hz, 1H), 6.78 (s, 1H), 6.38 (d, J = 8.2 Hz, 1H), 4.54-4.42 (m, 1H), 4.28 (ABq, J = 20.6, 14.9 Hz, 2H), 4.08-3.95 (m, 1H), 3.84-3.75 (m, 1H), 3.44 (s, 3H), 3.09 (d, J = 4.9 Hz, 1H), 2.98 (d, J = 6.8 Hz, 2H), 2.81 (dd, J = 12.3, 4.9 Hz, 1H), 2.77-2.69 (m, 3H), 1.56-1.33 (m, 5H), 1.33-1.24 (m, 4H), 1.07 (t, J = 6.9 Hz, 6H), 1.01–0.96 (m, 2H), 0.87 (t, J = 7.1 Hz, 3H). ¹³C NMR (125 MHz, CDCl₃): δ 171.67, 167.77, 137.47, 134.36, 130.68, 129.20, 128.58, 128.06, 126.97, 126.69, 126.05, 120.23, 118.05, 117.83, 71.81, 66.05, 52.15, 51.63, 50.99, 43.01, 40.92, 39.60, 38.81, 35.05, 22.46, 18.90, 17.89, 14.15, 13.86, 12.64. HRMS-ESI (m/z): $[M + H]^+$ calcd for C34H48N5O5S, 638.3376; found, 638.3371.

Determination of X-ray Structure of β -Secretase–Inhibitor 5 **Complex.** Expression and purification of recombinant human β secretase, crystal growing, inhibitor soaking of the crystal, and diffraction data collection were performed as previously described.⁸ The structure was determined by molecular replacement implemented with the program AMoRe using the C molecule of previously determined memapsin 2 structure (PDB ID: 1FKN) as a search model⁸ with removed inhibitor and water molecules. Rotation and translation functions followed by the rigid-body refinement with data from 15 to 3.5 Å resolution in space group P21 gave unambiguous solutions for the four memapsin 2 molecules in the asymmetric unit. A random selection of 7% of reflections (9028 reflections) was set aside as the test set for cross-validation during the refinement. The refined model had well-defined electron density for the inhibitor, and its corresponding structure was built into the active site. The four molecules in the crystallographic asymmetric unit have essentially identical structures. The crystal form was determined to be monoclinic with a resolution of 2.0 Å. The unit cell parameters are a = 86.4 Å, b =130.3 Å, c = 88.4 Å, and $\beta = 97.5$. The coordinates and structure

Journal of Medicinal Chemistry

factors of the β -secretase and **5** complex have been deposited in Protein Data Bank²⁸ with PDB ID: 4GID.

ASSOCIATED CONTENT

S Supporting Information

HPLC and HRMS data of inhibitors 4-9 and 18-22; crystallographic data collection and refinement statistics for inhibitor 5. This material is available free of charge via the Internet at http://pubs.acs.org.

Accession Codes

The PDB accession code for **5**-bound β -secretase X-ray structure is 4GID.

AUTHOR INFORMATION

Corresponding Author

*Tel: 765-494-5323. Fax: 765-496-1612. E-mail: akghosh@ purdue.edu.

Notes

The authors declare no competing financial interest.

ACKNOWLEDGMENTS

Financial support by the National Institutes of Health (AG 18933) is gratefully acknowledged. We thank Dr. Cuthbert D. Martyr (Purdue University) for his help with the MS data.

ABBREVIATIONS

AD, Alzheimer's disease; BACE 1, β -site APP cleaving enzyme 1; BACE 2, β -site APP cleaving enzyme 2; APP, β -amyloid precursor protein; CD, cathepsin D

REFERENCES

(1) Goedert, M.; Spillantini, M. G. A Century of Alzheimer's Disease. *Science* **2006**, *314*, 777–781.

(2) Selkoe, D. J.; Schenk, D. Alzheimer's Disease: Molecular Understanding Predicts Amyloid-Based Therapeutics. *Annu. Rev. Pharmacol. Toxicol.* 2003, 43, 545–584.

(3) Citron, M. Alzheimer's Disease: Strategies for Disease Modification. *Nat. Rev. Drug Discovery* **2010**, *9*, 387–398.

(4) Billings, L. M.; Oddo, S.; Green, K. N.; McGaugh, J. L.; LaFerla, F. M. Intraneuronal A β Causes the Onset of Early Alzheimer's Disease-Related Cognitive Deficits in Transgenic Mice. *Neuron* **2005**, *45*, 675–688.

(5) Ghosh, A. K.; Brindisi, M.; Tang, J. Developing β -Secretase Inhibitors for Treatment of Alzheimer's Disease. *J. Neurochem.* **2012**, 120, 71–83.

(6) Tang, J.; Hong, L.; Ghosh, A. K. The Discovery of β -Secretase and Development Toward a Clinical Inhibitor for AD: An Exciting Academic Collaboration. In *Aspartic Acid Proteases as Therapeutic Targets*; Ghosh, A. K., Ed.; Wiley-VCH: Weinheim, 2010; Vol. 45, pp 413–440.

(7) Ghosh, A. K.; Shin, D.; Downs, D.; Koelsch, G.; Lin, X.; Ermolieff, J.; Tang, J. Design of Potent Inhibitors for Human Brain Memapsin 2 (β -Secretase). *J. Am. Chem. Soc.* **2000**, *122*, 3522–3523. (8) Hong, L.; Koelsch, G.; Lin, X.; Wu, S.; Terzyan, S.; Ghosh, A. K.;

Zhang, X. C.; Tang, J. Structure of the Protease Domain of Memapsin 2 (β -Secretase) Complexed with Inhibitor. *Science* **2000**, 290, 150–153.

(9) Ghosh, A. K.; Kumaragurubaran, N.; Hong, L.; Kulkarni, S.; Xu, X.; Miller, H. B.; Reddy, D. S.; Weerasena, V.; Turner, R.; Chang, W.; Koelsch, G.; Tang, J. Potent Memapsin 2 (β -Secretase) Inhibitors: Design, Synthesis, Protein-Ligand X-ray Structure, and in vivo Evaluation. *Bioorg. Med. Chem. Lett.* **2008**, *18*, 1031–1036.

(10) Chang, W.; Huang, X.; Downs, D.; Cirrito, J. R.; Koelsch, G.; Holtzman, D. M.; Ghosh, A. K.; Tang, J. β-Secretase Inhibitor GRL- 8234 Rescues Age-related Cognitive Decline in APP Transgenic Mice. *FASEB J.* **2011**, *25*, 775–784.

(11) Turner, R. T.; Loy, J. A.; Nguyen, C.; Devasamudram, T.; Ghosh, A. K.; Koelsch, G.; Tang, J. Specificity of Memapsin 1 and Its Implications on the Design of Memapsin 2 (β -Secretase) Inhibitor Selectivity. *Biochemistry* **2002**, *41*, 8742–8746.

(12) Diment, S.; Leech, M. S.; Stahl, P. D. Cathepsin D is Membrane-Associated in Macrophage Endosomes. *J. Biol. Chem.* **1988**, 263, 6901–6907.

(13) (a) Koike, M.; Nakanishi, H.; Saftig, P.; Ezaki, J.; Isahara, K.; Ohsawa, Y.; Schulz-Schaeffer, W.; Watanabe, T.; Waguri, S.; Kametaka, S.; Shibata, M.; Yamamoto, K.; Kominami, E.; Peters, C.; Figura, K.; Uchiyama, Y. Cathepsin D Deficiency Induces Lysosomal Storage with Ceroid Lipofuscin in Mouse CNS Neurons. *J. Neurosci.* **2000**, *20*, 6898–6906. (b) Saftig, P.; Hetman, M.; Schmahl, W.; Weber, K.; Heine, L.; Mossmann, H.; Koster, A.; Hess, B.; Evers, M.; von Figura, K. *EMBO J.* **1995**, *14*, 3599–3608.

(14) Ghosh, A. K.; Kumaragurubaran, N.; Hong, L.; Lei, H.; Hussain, K. A.; Liu, C.-F.; Devasamudram, T.; Weerasena, V.; Turner, R.; Koelsch, G.; Bilcer, G.; Tang, J. Design, Synthesis and X-ray Structure of Protein–Ligand Complexes: Important Insight into Selectivity of Memapsin 2 (β -Secretase) Inhibitors. J. Am. Chem. Soc. **2006**, 128, 5310–5311.

(15) (a) Labby, K. J.; Xue, F.; Kraus, J. M.; Ji, H.; Mataka, J.; Li, H.; Martásek, P.; Roman, L. J.; Poulos, T. L.; Silverman, R. B. Intramolecular Hydrogen Bonding: A Potential Strategy for More Bioavailable Inhibitors of Neuronal Nitric Oxide Synthase. *Bioorg. Med. Chem.* **2012**, *20*, 2435–2443. (b) Kuhn, B.; Mohr, P.; Stahl, M. Intramolecular Hydrogen Bonding in Medicinal Chemistry. *J. Med. Chem.* **2010**, *53*, 2601–2611.

(16) (a) Iserloh, U.; Cumming, J. N. Peptidomimetic BACE1 Inhibitors for Treatment of Alzheimer's Disease: Design and Evolution. In Aspartic Acid Proteases as Therapeutic Targets; Ghosh, A. K., Ed.; Wiley-VCH: Weinheim, 2010; Vol. 45, pp 441–479. (b) Coburn, C. A.; Stachel, S. J.; Jones, K. G.; Steele, T. G.; Rush, D. M.; DiMuzio, J.; Pietrak, B. L.; Lai, M.-T.; Huang, Q.; Lineberger, J.; Jin, L.; Munshi, S.; Holloway, M. K.; Espeseth, A.; Simon, A.; Hazuda, D.; Graham, S. L.; Vacca, J. P. BACE-1 Inhibition by a Series of ψ [CH₂NH] Reduced Amide Isosteres. *Bioorg. Med. Chem. Lett.* **2006**, 16, 3635–3638.

(17) Velmourougane, G.; Harbut, M. B.; Dalal, S.; McGowan, S.; Oellig, C. A.; Meinhardt, N.; Whisstock, J. C.; Klemba, M.; Greenbaum, D. C. Synthesis of New (–)-Bestatin-Based Inhibitor Libraries Reveals a Novel Binding Mode in the S1 Pocket of the Essential Malaria M1Metalloaminopeptidase. *J. Med. Chem.* **2011**, *54*, 1655–1666.

(18) Ghosh, A. K.; Kumaragurubaran, N.; Hong, L.; Kulkarni, S. S.; Xu, X.; Chang, W.; Weerasena, V.; Turner, R.; Koelsch, G.; Bilcer, G.; Tang, J. Design, Synthesis, and X-ray Structure of Potent Memapsin 2 (β -Secretase) Inhibitors with Isophthalamide Derivatives as the P2-P3-Ligands. *J. Med. Chem.* **2007**, *50*, 2399–2407.

(19) Andurkar, S. V.; Stables, J. P.; Kohn, H. Synthesis and Anticonvulsant Activities of (R)-(O)-Methylserine Derivatives. *Tetrahedron: Asymmetry* **1998**, *9*, 3841–3854.

(20) Charrier, N.; Clarke, B.; Cutler, L.; Demont, E.; Dingwall, C.; Dunsdon, R.; East, P.; Hawkins, J.; Howes, C.; Hussain, I.; Jeffrey, P.; Maile, G.; Matico, R.; Mosley, J.; Naylor, A.; O'Brien, A.; Redshaw, S.; Rowland, P.; Soleil, V.; Smith, K. J.; Sweitzer, S.; Theobald, P.; Vesey, D.; Walter, D. S.; Wayne, G. Second Generation of Hydroxyethylamine BACE-1 Inhibitors: Optimizing Potency and Oral Bioavailability. J. Med. Chem. 2008, 51, 3313–3317.

(21) Hubert, D. E.; Sally, R.; Simon, W. D. Tricyclic Indole Derivatives and Their Use in the Treatment of Alzheimer's Disease. WO 2004/094430 A1.

(22) Charrier, N.; Demont, E.; Dunsdon, R; Maile, G.; Naylor, A.; O'Brien, A.; Redshaw, S.; Theobald, P.; Vesey, D.; Walter, D. Synthesis of Indoles: Efficient Functionalisation of the 7-Position. *Synthesis* **2006**, 3467–3477.

Journal of Medicinal Chemistry

(23) Fleming, P. R.; Sharpless, K. B. Selective Transformations of Threo-2,3-dihydroxy Esters. J. Org. Chem. 1991, 56, 2869–2875.

(24) Memapsin 2 inhibition was measured using recombinant enzyme produced from *E. coli* expression. A fluorogenic substrate Arg-Glu(EDANS)-Glu-Val-Asn-Leu-Asp-Ala-Glu-Phe-Lys (Dabcyl)-Arg was used with a 0.47 μ M concentration of the enzyme in 0.1 M Na-acetate + 5% dimethylsulfoxide, pH 4.5, at 37 °C. The excitation wavelength was 350 nm, and the emission wavelength was 490 nm. For details, please see Ermolieff, J.; Loy, J. A.; Koelsch, G.; Tang, J. Proteolytic Activation of Recombinant Pro-memapsin 2 (Pro- β -secretase) Studied with New Fluorogenic Substrates. *Biochemistry* 2000, 39, 12450–12456.

(25) Chang, W. P.; Koelsch, G.; Wong, S.; Downs, D.; Da, H.; Weerasena, V.; Gordon, B.; Devasamudram, T.; Bilcer, G.; Ghosh, A. K.; Tang, J. In vivo Inhibition of $A\beta$ Production by Memapsin 2 (β -Secretase) Inhibitors. *J. Neurochem.* **2004**, *89*, 1409–1416.

(26) Patel, S.; Vuillard, L.; Cleasby, A.; Murray, C. W.; Yon, J. Apo and Inhibitor Complex Structures of BACE (β -Secretase). J. Mol. Biol. **2004**, 343, 407–416.

(27) Charrier, N.; Clarke, B.; Cutler, L.; Demont, E.; Dingwall, C.; Dunsdon, R.; Hawkins, J.; Howes, C.; Hubbard, J.; Hussain, I.; Maile, G.; Matico, R.; Mosley, J.; Naylor, A.; O'Brien, A.; Redshaw, S.; Rowland, P.; Soleil, V.; Smith, K. J.; Sweitzer, S.; Theobald, P.; Vesey, D.; Walter, D. S.; Wayne, G. Second Generation of BACE-1 Inhibitors Part 3: Towards Non-hydroxyethylamine Transition State Mimetics. *Bioorg. Med. Chem. Lett.* **2009**, *19*, 3674–3678.

(28) Berman, H. M.; Westbrook, J.; Feng, Z.; Gilliland, G.; Bhat, T. N.; Weissig, H.; Shindyalov, I. N.; Bourne, P. E. The Protein Data Bank. *Nucleic Acids Res.* **2000**, *28*, 235–242.